Subscribe To
Merck to present extensive new research demonstrating significant progress in the treatment of certain earlier stage cancers and in advancing broad oncology pipeline at 2023 asco annual meeting
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck asco Curtain Raiser....
May 15, 2023, 6:45 am
Tech titans aren't the only game in town, consider biotech and, yes, financials
The Regional Bank Fiasco is a classic “Baby with the Bathwater” scenario. Rising rates are great fo...
May 14, 2023, 9:08 pm
National health investors, inc. (nhi) q1 2023 earnings call transcript
National Health Investors, Inc. (NYSE:NHI ) Q1 2023 Earnings Conference Call May 10, 2023 12:00 PM ET Company Participants Dana Hambly - Director of I...
May 10, 2023, 3:25 pm
Pasco scientific launches new summer institutes for science teaching and learning
Three-day, Intensive Professional Development Prepares Science Teachers to Transform Hands-On Learning for Students ROSEVILLE, Calif., May 09, 2023 (G...
May 9, 2023, 6:27 pm
Bud light's sales drop is accelerating amid dylan mulvaney fiasco — and is now spilling into other bud brands
“Anecdotally we are hearing that sales of Bud Light are declining more rapidly at bars and restaurants where some consumers don't want to be seen dr...
May 9, 2023, 5:52 pm
Atossa therapeutics to present insights from ongoing evangeline clinical trial at asco annual meeting
Atossa Therapeutics, Inc has announced that it will present a Trial in Progress poster for the Phase 2 clinical study of (Z)-endoxifen in premenopausa...
May 9, 2023, 10:23 am
Lodestar battery metals updates peñasco quemado project mre with major inferred silver resource
Lodestar Battery Metals Corp. (TSX-V:LSTR, OTCQB:SVTNF) said it has filed an independent technical report for the Peñ...
May 8, 2023, 9:31 am
Anheuser-busch cans ‘third-party ad agency' tied to dylan mulvaney fiasco: sources
The company's global CEO Michel Doukeris this week came out swinging at the "misinformation" being spread about the extent of Bud Light's relationship...
May 5, 2023, 2:25 pm
Nzd/usd refreshes day high at 0.6230 as us banking woes renewed, us nfp eyed
NZD/USD has printed a fresh day’s high at 0.6225 as fears of a US banking fiasco renewed. Rising expe...
May 4, 2023, 1:59 am
Business first bancshares, inc. (bfst) q1 2023 earnings call transcript
Business First Bancshares, Inc. (NASDAQ:BFST ) Q1 2023 Results Conference Call April 27, 2023 5:30 PM ET Company Participants Matt Sealy - SVP and Dir...
April 29, 2023, 2:59 pm
Swiss broker dukascopy’s profit surges 200% to second-highest in history
Dukascopy Bank, a Swiss retail forex and CFDs brokerage and retail banking provider, released its annua...
April 27, 2023, 6:16 pm
Tempest announces tpst-1495 poster presentation at the 2023 asco annual meeting
BRISBANE, Calif., April 26, 2023 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in...
April 26, 2023, 10:41 pm
Erasca announces two poster presentations at the 2023 asco annual meeting
Posters will feature preliminary Phase 1b combination data for potential best-in-class ERK1/2 inhibitor ERAS-007 with encorafenib and cetuximab or wit...
April 26, 2023, 9:00 pm
Aravive announces poster presentation on batiraxcept at 2023 asco annual meeting
HOUSTON, April 26, 2023 (GLOBE NEWSWIRE) — Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing target...
April 26, 2023, 9:00 pm
Orascom development holding ag: announces results of rights offering
Orascom Development Holding AG announces the results of the rights offering: Until the end of the right...
April 26, 2023, 4:59 pm
Hookipa to present a trial in progress poster on its prostate cancer phase 1/2 clinical trial at asco
NEW YORK and VIENNA, Austria, April 26, 2023 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class ...
April 26, 2023, 3:30 pm
Cullinan oncology to present first clinical data evaluating novel anti-mica/b antibody, cln-619, in patients with advanced solid tumors at asco 2023
CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) — Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic...
April 26, 2023, 2:08 pm
Allogene therapeutics announces presentation of phase 1 data from the allo-501/501a trials in large b cell lymphoma at the american society of clinical oncology (asco) annual meeting
SOUTH SAN FRANCISCO, Calif., April 26, 2023 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pi...
April 26, 2023, 2:06 pm
Galera to present one-year reductions in cisplatin-related chronic kidney disease data from roman trial at 2023 american society of clinical oncology (asco) annual meeting
MALVERN, Pa., April 26, 2023 (GLOBE NEWSWIRE) — Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on deve...
April 26, 2023, 2:00 pm
Day one announces abstracts accepted for presentation at the 2023 american society of clinical oncology (asco) annual meeting
New clinical data from registrational FIREFLY-1 study to be featured as an oral presentation Trial-in-progress poster from FIREFLY-2 and healthcare re...
April 26, 2023, 1:31 pm